Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congres
Go back to Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congres| Beam Inc. (NASDAQ: BEAM) | Delayed: 25.00 +0.33 (1.34%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.67 | 52 Week High | $83.60 | |||
| Open | $24.92 | 52 Week Low | $82.96 | |||
| Day High | $25.18 | P/E | 11.16 | |||
| Day Low | $24.26 | EPS | $2.24 | |||
| Volume | 511,660 | |||||
| Beam Inc. (NASDAQ: BEAM) | Delayed: 25.00 +0.33 (1.34%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.67 | 52 Week High | $83.60 | |||
| Open | $24.92 | 52 Week Low | $82.96 | |||
| Day High | $25.18 | P/E | 11.16 | |||
| Day Low | $24.26 | EPS | $2.24 | |||
| Volume | 511,660 | |||||
